Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of traditional Chinese medicine composition in preparation of medicament for treating renal toxicity after chemoradiotherapy and cardiovascular and cerebrovascular diseases

A technology for cardiovascular and cerebrovascular diseases and compositions, which can be used in cardiovascular system diseases, drug combinations, urinary system diseases, etc., and can solve problems such as no discovery.

Active Publication Date: 2014-07-02
XIAN SHIJISHENGKANG PHARMA IND
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In the prior art, although rhubarb, astragalus, and salvia have been used alone or in combination for the treatment of nephrotoxicity or cardiovascular and cerebrovascular diseases after radiotherapy and chemotherapy, the inventor has not found any report on the specific proportion of the drug of the present invention for the treatment of the above diseases or literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of traditional Chinese medicine composition in preparation of medicament for treating renal toxicity after chemoradiotherapy and cardiovascular and cerebrovascular diseases
  • Application of traditional Chinese medicine composition in preparation of medicament for treating renal toxicity after chemoradiotherapy and cardiovascular and cerebrovascular diseases
  • Application of traditional Chinese medicine composition in preparation of medicament for treating renal toxicity after chemoradiotherapy and cardiovascular and cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0029] Experimental Example 1 The protective effect of the present invention on mouse kidney after radiation

[0030] 1. Experimental animals BALB / c pure line mice, half male and half female, weighing 20±2g, aged 7-8 weeks, were purchased from the Experimental Animal Center of Fourth Military Medical University.

[0031] 2. Experimental drug The drug of the present invention and Shenkang injection contain 2.5 g of crude drug per milliliter, both provided by Xi'an Century Shengkang Pharmaceutical Co., Ltd.

[0032] 3. Experimental method After 3 days of adaptive feeding, 40 pure BALB / c mice were randomly divided into 4 groups, 10 mice in each group, namely blank group, simple radiation group, the present invention group and Shenkang injection group. Except for the normal feeding of the blank group, the other three groups were irradiated with medical linear accelerator and 6MeV ray, with a dose of 2.5Gy / time, once every other day, for a total of 3 times. The present invention ...

experiment example 2

[0041] Experimental example 2 The protective effect of the present invention on cisplatin-induced renal injury rats

[0042] 1. Experimental animals SD rats, half male and half male, weighing 180±20 g, were purchased from the Experimental Animal Center of Fourth Military Medical University.

[0043]2. Experimental drug The drug of the present invention and Shenkang injection contain 2.5g of crude drug per milliliter, provided by Xi'an Century Shengkang Pharmaceutical Co., Ltd.; cisplatin for injection, specification 10mg / bottle, produced by Qilu Pharmaceutical Factory.

[0044] 3. Experimental method Get 60 rats, carry out adaptive feeding after 3 days, rats are divided into blank group, cisplatin group, the present invention group and Shenkang injection group at random, except that the blank group is raised normally every day, The cisplatin group, the present invention group and the Shenkang injection group were given cisplatin 0.48 mg / kg by intraperitoneal injection every ...

experiment example 3

[0066] Experimental Example 3 Therapeutic effect of the present invention on cerebral ischemia rats

[0067] 1. Experimental materials SD rats, clean grade, 180-220g, half male and half male, provided by the Experimental Animal Center of Fourth Military Medical University.

[0068] 2. Experimental drug The present invention and Shenkang injection contain 2.5g of crude drug per milliliter, provided by Xi'an Century Shengkang Pharmaceutical Co., Ltd.

[0069] 3. Experimental method SD rats were randomly divided into 4 groups, namely the sham operation group, the model group, the present invention group and the Shenkang injection group. One week before modeling, the present invention group and the Shenkang injection group were alternately injected with corresponding drugs in the tail vein and abdominal cavity; the model group and the sham operation group were injected with equal volumes of glucose injection, each given 1ml / 100g, and each group was administered daily once. One...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of a traditional Chinese medicine composition in preparation of a medicament for treating renal toxicity after chemoradiotherapy and cardiovascular and cerebrovascular diseases. The traditional Chinese medicine composition comprises the components, namely rheum officinale, astragalus membranaceus and root of red-rooted salvia. An experiment proves that the traditional Chinese medicine composition effectively treats and relieves renal toxicity caused by tumor radiation and chemotherapy, and simultaneously has an obvious treatment effect on ischemic cardiovascular and cerebrovascular diseases, for example, cerebellar infarction size is reduced, the cerebral ischemic injury is improved, the infarct size of myocardial ischemia reperfusion in rats is reduced, and the content of methylene dioxyamphetamine (MDA) and NOS is reduced.

Description

technical field [0001] The invention relates to the application of a traditional Chinese medicine composition in preparing and treating nephrotoxicity and cardiovascular and cerebrovascular diseases after radiotherapy and chemotherapy. Specifically, it belongs to the field of medical use. Background technique [0002] Tumor is one of the most serious diseases that endanger human life and health. With the improvement of people's living standards, the incidence of tumor is also increasing year by year. Conventional methods used to treat tumor diseases have certain toxic effects on many organs, especially the toxicity to the kidney, which has attracted more and more attention. Studies have shown that in the radiation treatment of tumor diseases, the radiation dose is 1000-2000 rads, and the kidneys will not produce persistent pathological abnormalities within 2-3 weeks; when the dose is 2300-2500 rads, it will be visible after 4-5 weeks Histopathological changes in the early ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/708A61P13/12A61P9/00
Inventor 曹凤君吕延英詹芳王光建赵兴王俊平
Owner XIAN SHIJISHENGKANG PHARMA IND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com